Safety and Efficacy of the Full Face Applications of Variable Doses of a Commercial Botulinum Toxin Type a (Dysport®)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01032954
Recruitment Status : Unknown
Verified December 2009 by Brazilan Center for Studies in Dermatology.
Recruitment status was:  Active, not recruiting
First Posted : December 16, 2009
Last Update Posted : July 7, 2010
Information provided by:
Brazilan Center for Studies in Dermatology

December 15, 2009
December 16, 2009
July 7, 2010
November 2009
November 2010   (Final data collection date for primary outcome measure)
Whoqol(Quality of life questionaire) [ Time Frame: Visit 5 ]
Same as current
Complete list of historical versions of study NCT01032954 on Archive Site
  • Photographs evaluation - independent dermatologists [ Time Frame: Visit 2 (week 4) ]
  • Photographs evaluation - independent dermatologists [ Time Frame: Visit 3 (week 16) ]
  • Photographs evaluation - independent dermatologists [ Time Frame: visit 4 (week 20) ]
  • Photographs evaluation - independent dermatologists [ Time Frame: visit 5 (week 24) ]
Same as current
Not Provided
Not Provided
Safety and Efficacy of the Full Face Applications of Variable Doses of a Commercial Botulinum Toxin Type a (Dysport®)
Phase Iv Study On The Safety And Efficacy Of The Full Face Applications Of Variable Doses Of 125 To 250 Units Of A Commercial Botulinum Toxin Type A (Dysport®)
This is an open-label and phase IV study of full face injections of variable doses of BT-A. As it is an open-label and not blind study, both investigator and subjects will know the injection local and doses of the study drug. Patients will be randomized into 3 different groups. Each group will receive a specific dose according with the indication evaluated by the investigator. Six visits will be schedule in this study.

4.2 Methodology

4.2.1 Patient evaluation After providing written informed consent, subject's eligibility will be assessed at a Screening Visit. The subject's general medical history will be recorded. This includes demographic data, history of surgical and cosmetic procedures, dermatological assessment, physical examination, and prior concomitant medications. A pregnancy test will also be performed. Severity of wrinkles

One sub-investigator will rate the wrinkles with the following validated severity scales for the main areas of the face in relaxed mode and under maximal contraction, at visit 0, visits 2 (week 4) and 3 (week 16):

  • Clinical 0-3 score for glabellar frown lines7 (Annex 4)
  • Photonumeric Atlas for the Assessment of Crow's Feet Severity8 (Annex 5)
  • Photonumerical Atlas for the Assessment of Forehead Wrinkle Severity9 (Annex 6)
  • Marionette Lines Grading Scale10 (Annex 7) Standard set of photographs will be taken

At Screening , 2, 3, 4 and 5 visits, photographs will be taken:

All the photographs will be taken in a standardized photographic mode with fixed position of the camera. A guideline with examples of standardized photos with delimit standardized positions will be provided to the person responsible to take the photos.

In the photographs, each research subject will be identified by a tag containing a reference to the study, the number of the research subject and the control date. The research subjects should wash their faces before the photographic procedure to remove excess oil and all make up will be removed. All the pictures will be taken at the same room and under same parameters.

The photograph set consist of

  • Full face frontal view relaxed;
  • One set of photographs relaxed and contracted of each indication that patient will be or was treated in this study.

At the end of the study, two independent evaluators (dermatologists) will assess before and after pictures in a blinded manner. This evaluation will be done to assess the efficacy of BT-A in the injected areas not assessed by the scales.

4.2.3 Evaluation of Quality of Life and patient-reported complains, outcomes and satisfaction Patients will be invited to answer the WHOQoL bref (Annex 2). They will also answer a questionnaire regarding their believes, expectations and spontaneous complaints before and after treatment (Annex 3). This questionnaires will be answered by the patients in the visits: screening, 2, 3, 4 e 5. .

4.2.4 Groups of treatment

Subjects will be assigned to one of the three following treatment groups, according with the total dose received in visit 1:

  • Group 1: 30 subjects who received 125 to 170 U of BT-A (Dysport®)
  • Group 2: 30 subjects who received 171 to 210 U of BT-A (Dysport®)
  • Group 3: 30 subjects who received 211 to 250 U of BT-A (Dysport®)

4.2.5 Reconstitution of the study product and Treatment Administration An independent, experienced and registered pharmacist will be the assigned to carry through the reconstitution of the products. She will prepare the dilutions and the syringes of the product (DYSPORT®) immediately prior to the injections.

The dilutions of DYSPORT® 500 Units per vial will be made with 2 mL of 0.9% sterile saline, using 3 mL syringes and a 21G needle, giving a concentration of 250 Units/mL or 2.5Units/0.01mL of the reconstituted product.

An experienced dermatologist in the use of botulinum toxins (principal investigator - DH) will perform all the injections according to the indications and total number of units that will be injected according to the treatment plan, which aims to obtain the best results. She will only perform the injections and will not participate in other phases of this study.

The application of the BT-A will be made through BD Ultra-fine II 0.3cc syringes, with a 29G needle, 0.5cm in length (short needle).

Immediately after the application, the side effects will be verified and if needed, will be registered and managed.

Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Dynamic Wrinkles
Drug: Botulinum toxin

The following list shows the indications for eligibility and total doses that will be applied in each part of the face, according to the consensus meeting recommendations, at the 1 visit:

Upper face:

  • Crow's feet wrinkles - 70 U
  • Glabella - 50 U
  • Forehead - 40 U

Mid face:

  • Lower eyelid - 5 U
  • Nasal wrinkles - 20 U
  • Malar wrinkles - 10 U

Lower face:

  • Peri-oral wrinkles - 15U
  • Asymmetric smile or gummy smile - 5U
  • "Cellulitic chin" - 20U
  • Marionette lines - 25 U According to the patients needs, the doses can vary ±10% in terms of the amount of units that will be injected.

Patients will be allocated in each group according to the total dose received at visit 1(described above). At visit 2, all the patients will receive a touch-up of a standard dose of 25 Units of Dysport®, distributed on the treated areas according patient's needs.

  • Active Comparator: 125 to 170 U of BT-A
    Intervention: Drug: Botulinum toxin
  • Active Comparator: 171 to 210 U of BT-A
    Intervention: Drug: Botulinum toxin
  • Active Comparator: 211 to 250 U of BT-A
    Intervention: Drug: Botulinum toxin
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Same as current
November 2010
November 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Written Informed Consent;
  2. Subjects aged between 30 and 60 years;
  3. Skin Fitzpatrick Phototypes I to VI;
  4. Subjects that never received BT-A or who had previous injections of BT-A in no more than one third of the face with in the last 6 months;
  5. Subjects presenting at least two indications for treatment with BT-A in each third of the face;
  6. Medical history and physical examination which, based on the investigator's opinion, do not prevent the patient from taking part in the study and use the product under investigation;
  7. Subjects of childbearing age should present a negative urine pregnancy test (instant test) at baseline and should be using an effective contraceptive method (oral or injectable contraceptive, for at last three months, and use of preservative; subjects with: hysterectomy, oophorectomy or tubal ligation);
  8. Availability of the patient throughout the duration of the study (24 weeks);
  9. Subjects that agree not to undergo other cosmetic or dermatological procedures during the study;
  10. Subjects with sufficient schooling and awareness to enable them to cooperate to the degree required by the study protocol.

Exclusion Criteria:

  1. Pregnant women or women intending to become pregnant during the study;
  2. Subjects participating in other clinical trials;
  3. Presence of scars on the face that may interfere with the result of study;
  4. Subjects with neoplastic, muscular or neurological diseases;
  5. Concurrent use of treatments that affect neuromuscular transmission, such as curare-like depolarizing agents, lincosamides, polymyxins, anticholinesterases affecting the striated muscle and aminoglycoside antibiotics.
  6. Subjects with inflammation or active infection in the face;
  7. Subjects with a history of sensitivity to the components of the formula;
  8. Subjects with prior history of eyelid ptosis; marked facial asymmetry, excessive dermatochalasis, deep dermal scarring or thick sebaceous skin.
  9. Subjects presenting myasthenia gravis, Eaton-Lambert Syndrome and motor neuron diseases;
  10. Subjects with coagulation disorders or using anticoagulants;
  11. Subjects with known systemic autoimmune diseases;
  12. Subjects clinically diagnosed anxiety disorder or any significant psychiatric disorder (e.g. depression) that, in the opinion of the Evaluator, might interfere with the Subject's participation in the study;
  13. Subjects with a history of medical treatment non-adherence or showing unwillingness to adhere to the study protocol.
Sexes Eligible for Study: All
30 Years to 60 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Doris M Hexsel, Brazilian Center for Studies in Dermatology
Brazilan Center for Studies in Dermatology
Not Provided
Principal Investigator: Doris M Hexsel, MD Brazilian Center for Studies in Dermatology
Brazilan Center for Studies in Dermatology
December 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP